Shanghai Kehua Bio-EngineeringLtd Past Earnings Performance
Past criteria checks 0/6
Shanghai Kehua Bio-EngineeringLtd has been growing earnings at an average annual rate of 2.3%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 13.6% per year.
Key information
2.3%
Earnings growth rate
2.2%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 13.6% |
| Return on equity | -6.1% |
| Net Margin | -15.6% |
| Next Earnings Update | 30 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shanghai Kehua Bio-EngineeringLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,038 | -318 | 838 | 223 |
| 31 Dec 23 | 2,428 | -234 | 875 | 241 |
| 30 Sep 23 | 3,491 | -241 | 1,176 | 279 |
| 30 Jun 23 | 7,463 | 946 | 1,496 | 334 |
| 31 Mar 23 | 7,383 | 1,004 | 1,402 | 293 |
| 31 Dec 22 | 6,970 | 972 | 1,315 | 250 |
| 30 Sep 22 | 6,509 | 1,313 | 913 | 218 |
| 30 Jun 22 | 3,357 | 418 | 654 | 138 |
| 31 Mar 22 | 3,822 | 530 | 730 | 144 |
| 01 Jan 22 | 4,854 | 850 | 824 | 148 |
| 30 Sep 21 | 5,316 | 1,003 | 961 | 163 |
| 30 Jun 21 | 5,095 | 962 | 905 | 153 |
| 31 Mar 21 | 5,072 | 968 | 921 | 157 |
| 31 Dec 20 | 4,155 | 675 | 846 | 147 |
| 30 Sep 20 | 3,215 | 396 | 768 | 106 |
| 30 Jun 20 | 2,750 | 256 | 723 | 91 |
| 31 Mar 20 | 2,445 | 203 | 644 | 74 |
| 31 Dec 19 | 2,414 | 202 | 653 | 66 |
| 30 Sep 19 | 2,285 | 215 | 621 | 51 |
| 30 Jun 19 | 2,140 | 210 | 600 | 47 |
| 31 Mar 19 | 2,044 | 209 | 554 | 44 |
| 31 Dec 18 | 1,990 | 208 | 499 | 42 |
| 30 Sep 18 | 1,926 | 233 | 458 | 38 |
| 30 Jun 18 | 1,817 | 228 | 398 | 51 |
| 31 Mar 18 | 1,685 | 223 | 380 | 43 |
| 31 Dec 17 | 1,594 | 218 | 360 | 36 |
| 30 Sep 17 | 1,497 | 214 | 317 | 21 |
| 30 Jun 17 | 1,458 | 221 | 336 | 0 |
| 31 Mar 17 | 1,417 | 220 | 329 | 0 |
| 31 Dec 16 | 1,397 | 232 | 324 | 0 |
| 30 Sep 16 | 1,324 | 225 | 319 | 0 |
| 30 Jun 16 | 1,266 | 224 | 292 | 0 |
| 31 Mar 16 | 1,198 | 216 | 288 | 0 |
| 31 Dec 15 | 1,156 | 211 | 271 | 0 |
| 30 Sep 15 | 1,168 | 237 | 249 | 0 |
| 30 Jun 15 | 1,196 | 261 | 240 | 0 |
| 31 Mar 15 | 1,225 | 274 | 225 | 0 |
| 31 Dec 14 | 1,218 | 292 | 219 | 0 |
| 30 Sep 14 | 1,214 | 291 | 224 | 0 |
| 30 Jun 14 | 1,185 | 296 | 223 | 0 |
| 31 Mar 14 | 1,139 | 292 | 219 | 0 |
| 31 Dec 13 | 1,114 | 288 | 215 | 0 |
| 30 Sep 13 | 1,063 | 281 | 215 | 0 |
Quality Earnings: 002022 is currently unprofitable.
Growing Profit Margin: 002022 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002022 is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.
Accelerating Growth: Unable to compare 002022's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 002022 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: 002022 has a negative Return on Equity (-6.06%), as it is currently unprofitable.